The historical rank and industry rank for Alexza Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:
ALXA's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 21.73 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Alexza Pharmaceuticals Price-to-Free-Cash-Flow Historical Data
The historical data trend for Alexza Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alexza Pharmaceuticals's Price-to-Free-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, Alexza Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alexza Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alexza Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Alexza Pharmaceuticals's Price-to-Free-Cash-Flow falls into.
Alexza Pharmaceuticals's Share Price of today is $0.935. Alexza Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Alexza Pharmaceuticals Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Alexza Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexza Pharmaceuticals (Alexza Pharmaceuticals) Business Description
Alexza Pharmaceuticals Inc was incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc. In June 2001, it changed the name to Alexza Corporation and in December 2001 it became Alexza Molecular Delivery Corporation. In July 2005, it changed the name to Alexza Pharmaceuticals, Inc. It is a pharmaceutical company, engaged in the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. ADASUVE is its only approved product & there is one product candidate in active development, AZ-002 (Staccato alprazolam), which is being developed for the treatment of acute repetitive seizures, sometimes called cluster seizures or ARS. ADASUVE, or Staccato loxapine, and its product candidates are based on its proprietary technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience. The pharmaceutical and biotechnology industries are intensely competitive. Many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations are actively engaged in research and development of products targeting the same markets as ADASUVE and its other product candidates. The names "Alexza Pharmaceuticals," "Alexza," "Staccato" and "ADASUVE" are trademarks of the Company. It helds 195 issued and allowed U.S. and international patents. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of the Company's product candidates are subject to extensive regulation by governmental authorities in the United States and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXA has been successfully added to your 